Monday, November 9, 2020

IMX-110 - Cancer Drug Components and Design



A lawyer and graduate of Loyola Law School in Los Angeles, Ben Lyon serves as a vice president at Immix Biopharma. Also, as chief legal officer, attorney Ben Lyon handles executive-level responsibilities at Immix.

Recently, Immix Biopharma - an international privately-held cancer research biopharmaceutical firm - developed IMX-110. A first-in-class combination therapy, IMX-110 is a cancer resistance inhibitor. However, rather than directly kill cancer cells (and cause collateral damage to healthy normal cells) Immix's combination reactivates programmed cell death (apoptosis) that naturally occurs in cancer cells, which leads to their death. IMX-110 has demonstrated pre-clinical efficacy for various cancers - including triple-negative breast, ovarian, colorectal, pancreatic tumor, and multiple myeloma and more recently for various forms of sarcoma.

A combination of NF-kB/Stat3/pan-kinase inhibitor curcumin and a trace amount of doxorubicin packed in a nano-sized delivery system allows the drug to carry out optimal tumor penetration. IMX-110 binds well with specific target molecules and delivers a sufficient concentration of active chemicals to target key areas in cells. Compared to doxorubicin alone, IMX-110 is five times as efficient in inducing cancer cell apoptosis. 

Friday, October 16, 2020

Published: Summary of Tech M&A Activity in H1, 2020 — Analysis from PwC


I published “Summary of Tech M&A Activity in H1, 2020 — Analysis from PwC” on @Medium https://ift.tt/31aIOOP

Calumino’s Eve - A Specialized IoT System for Home Care Centers

 

Tuesday, September 8, 2020

Member Resources Provided by the SVAGC

Attorney Ben Lyon leverages years of experience as a general counsel and board member in his current role as vice president at Immix Biopharma. An expert in deal making and transactions, attorney Ben Lyon also holds membership with professional organizations such as the California State Bar and the Silicon Valley Association of General Counsel (SVAGC). Mr. Lyon also currently serves as a member of the Board of Directors of the SVAGC.

Since its organization more than thirty two years ago, the SVAGC has provided a platform for general counsel to network and meet professionally. The organization, which operates as a nonprofit, organizes a series of member's only monthly luncheons providing regular briefings on cutting edge legal topics and practices which are highly relevant to Silicon Valley General Counsel. SVAGC also opens its doors once a year at the Santa Clara Convention Center by holding the largest annual conference of its kind providing in depth updates on a variety of current topics, e.g. global intellectual property, advanced IP, tech commerce/exports, life sciences, global corporate and regulatory, product and privacy issues, attended by over 200 legal departments of technology and life sciences companies from the San Francisco Bay Area.

The SVAGC also maintains a website with a members-only area that is packed with professional resources and materials. In addition to a monthly newsletter, announcements, and access to special offers, members have access to CLE presentation supplements and handbooks. A range of administrative materials are also available on the website, including member support, rosters, and organizational policies. Finally, members can access a member dues invoice to pay their annual fees.

For further information on the SVAGC, visit www.ivyevents.com/svagc.